Navigation Links
AAAS decries latest stem cell veto

The President has again vetoed the Stem Cell Research Enhancement Act, which would expand federal support for embryonic stem cell research. AAAS, the world’s largest general scientific society, stands with a broad coalition of Americans spanning all parties and faiths that supports this bill.

The scientific consensus is that embryonic stem cell research is an extremely promising approach to developing more effective treatments for devastating conditions like diabetes, spinal cord injuries, and Parkinson’s disease. The bill would mandate that such research be allowed to compete for federal funding while following strict ethical guidelines.

The Executive Order is not a substitute for the Stem Cell Research Enhancement Act. The new approaches addressed by the order are still in the early stages of development and appear to already be eligible for NIH funding. AAAS strongly believes that it is only through federal support of diverse avenues of stem cell research that we may better understand the potential value and limitations of each approach.

During his tenure the President has acknowledged that it is a critical time for the American scientific enterprise, therefore it is disappointing that he has chosen to maintain restrictions on such a promising area of research. AAAS will continue to support the interests of scientists and patients in fostering medical progress. The American Association for the Advancement of Science (AAAS) on Wednesday expressed disappointment with the decision by President George W. Bush to veto a landmark stem cell research funding bill.

The measure would have lifted restrictions on federal funding of medical research using embryonic stem cells, which proponents say would be derived from microscopic embryos left over and due to be discarded after in vitro fertility treatments. Current U.S. policy limits such funding to fewer than 20 stem cell lines that had been created when the president first announce d U.S. policy in 2001.

"Our concern is that this action has the potential to delay development of important new therapies by cutting off a promising avenue of research," said Alan I. Leshner, the chief executive officer of AAAS and executive publisher of the journal Science.

The president vetoed a similar bill that passed the Senate and House of Representatives last year. This year's measure won strong bi-partisan support in the U.S. House and Senate, but fell just short of the two-thirds supermajority needed to override the veto.

While Bush signed a separate Executive Order to support other stem cell research, AAAS "strongly believes" that all avenues of stem cell research must be explored, the non-partisan association said a statement.

The following is the full text of the AAAS statement:

"The President has again vetoed the Stem Cell Research Enhancement Act, which would expand federal support for embryonic stem cell research. AAAS, the world's largest general scientific society, stands with a broad coalition of Americans spanning all parties and faiths that supports this bill.

"The scientific consensus is that embryonic stem cell research is an extremely promising approach to developing more effective treatments for devastating conditions like diabetes, spinal cord injuries, and Parkinson's disease. The bill would mandate that such research be allowed to compete for federal funding while following strict ethical guidelines.

"The Executive Order is not a substitute for the Stem Cell Research Enhancement Act. The new approaches addressed by the order are still in the early stages of development and appear to already be eligible for NIH funding. AAAS strongly believes that it is only through federal support of diverse avenues of stem cell research, including especially embryonic stem cell research, that we may better understand the potential value and limitations of each approach.

"During his tenure the President has acknowledged that it is a critical time for the American scientific enterprise, therefore it is disappointing that he has chosen to maintain restrictions on such a promising area of research. AAAS will continue to support the interests of scientists and patients in fostering medical progress."


'"/>

Source:American Association for the Advancement of Science


Related biology news :

1. NHGRI announces latest sequencing targets

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today that Edward Lanphier , Sangamo,s president and ... progress of Sangamo,s ZFP Therapeutic ® development programs ... 2:40 pm ET on Thursday, February 11, 2016, at ... Conference. The conference is being held in ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today provided an update on the Company,s ... of Texas and announcing that ... Partes Re-examination ("IPR") proceedings that VTech and Uniden ... initiated on only certain claims of two of the ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... other cuvette manufacturers is their supercharged customer service and their extensive database of glass ... flow of inside information, they have recently revamped their manufacturing techniques to reduce lead ...
Breaking Biology Technology: